SYMPOSIA

More documents

Recommendations

Info

(±)-3-4-methylenedioxymethamphetamine S36 1-benzylpiperazine S36 5-HT1B A-161T S108 Absence convulsion S118 Absenteeism S150 Abuse S180 Academic achievement S154 Academic performance S58 Acceptance S105 Access S156 Access to health care S156 Addiction S54, S42, S83, S109, S151, S155 ADHD S57, S66, S73, S96, S97, S136, S148 Adolescence S96 Adolescents S126, S153 ADRA2A S148 Adult ADHD S159 Adult attention deficit hyperactivity disorder S163 Affective disorder S161 Agmatine S166, S169 Agranulocytosis S46 AHP S198 Alcohol S155 Alcohol abuse S173, S174 Alcohol dependence S108 Alexithymia S56 Alkaline phosphatase S116 Alloxan S116 Alzheimer’s disease S52, S198 Amenorrhea S135 Amisulprid S160, S200 Amplified perception of somatic sensations S178 Amygdala S110, S133 Anger S138 Animal model of depression S140 Anorexia S92 Anorexia nervosa S130, S195 Antidepressant S38, S39, S43, S51, S81, S121, S136, S140 Antiepileptic S182 Antihypertensives S198 Antioxidant S170 Antioxidant vitamins S74 Antipsychotic S63, S135, S144, S149, S167 Antipsychotic development S50 Antipsychotic drug S180, S196 Antisocial personality disorder S163 Anxiety S69, S163, S132, S133, S141, S155 Anxiety disorders S40, S67, S68 Anxiety models S69 Anxiety symptom levels S153 Archive documents S181 Aripiprazole S135, S144, S152 Assessment S150, S151, S155 Atherosclerosis S143 Atomoxetine S136 Attachment S56 Attention deficit hyperactivity S58 Attention deficit hyperactivity disorder S95, S139 Atypical antipsychotics S63, S144, S164, S171 Augmentation S126 Autism S72 Avoiding behavior S122 Bacopa monniera S108, S153, S189 Basal ganglia hemorrhage S157 BDNF S91, S169 Behavioral therapy S185 Bilirubin S180 Binge eating S54 Biogenic amines S51 Biological rhythm S88, S89 Biomarker S102, S198 Bipolar S36, S57, S149 Bipolar affective disorder S169 Bipolar disorder S39, S59, S98, S100, S124, S126, S140, S142, S158 Blood level S142 Blood sugar S111 Body dysmorphic disorder S143 Brain imaging methods S195 Brain injury S136 Brain microdialysis S36 Brain-derived neurotrophic factor S176 Bright light S89 Bulimia S92 Bulimia nervosa S95, S194 Buprenorphine S35 Bupropion S113, S121, S143 C-fos S169 Cabergoline S124 Calcium S72, S123 Cannabis S37, S83, S130 Cannabis dependency S159 Caregiver burden S141 Catatonia S162 CBT S105, S106, S111 Cerebellar cognitive affective syndrome S138 Cerebellum S138, S195 Cerebral ischemia S112 Ceruloplasmin S170 Subject Index Character S34, S54 Chemotherapy S132 Chest pain without cardiac etiology S138 Child S36, S57 Childhood trauma S79, S86, S192 Children S74, S75, S97, S139 Cholinesterase inhibitors S136 Choreoathetoid movement S152 Chronic schizophrenia S125 Chronic unpredictable mild stress S166, S169 Chronotherapeutics S89 Cigarette S156 Clinical characteristics S82 Clinical manifestation S172 Clozapine S46, S126, S201 CNR1 1359 G/A S108 Co-morbidity S96, S97 Cognition S34, S91, S153 Cognitive behavior therapy S40, S41 Cognitive functions S83, S136, S138, S158, S188 Cognitive processing of emotions S56 Cognitive side effects S149 Combination drug therapy S40 Community care S129 Comorbidity S92, S95, S177 Complementary and alternative medicine S65 Confidence interval S104 Congenital hypogonadism S195 Corpus callosum S182 COX-2 inhibitor S184 Craving S156 CRH S51 Crisis team S129 Cultural differences S172 Cytochrome P450 2C9 S132 Cytokines S70 D-serine S50 Death S155 Deep brain stimulation S61 Dementia S62, S134 Depression S36, S38, S39, S43, S57,S60, S60, S64, S65, S70, S77, S78, S81, S82, S85, S87,S89, S130, S132, S139, S141, S145, S155, S161, S162, S163, S170, S178, S184, S190, S193, S198 Depression treatment S58 Depressive symmptom levels S153 Descriptive statistics S104 Development S74 Diabetic rats S116 Differential diagnosis S177 Diltiazem S119 Dissociation S192 Dissociative disorder S159 Dissociative symptoms S146 Divorce S144, S184 Don Juanism S52 Dopamine S49, S63 Dopamine agonists S124 DRD2 TaqIA S108 Drug S100, S103 Drug discovery S62 Drug induced S167 Drug-induced psychosis S182 Drug interactions S97 Drug safety S48 Drug utilization S168 Dual diagnosis S109 Duloxetine S115, S139 E-selectin S143 Eating disorders S54, S92, S93, S94, S130 Eating pattern S125 Echopraxia S200 Ecstasy S36 ECT 196 Ecuadorian population S132 Edema S196 Education S65 Education factors S128 EEG S110, S133 Effectiveness S151 Efficacy S38, S136, S201 Electroconvulsive therapy S174 Electromagnetic induction S117 EMDR S106, S127 Emotion regulation S40 Emotionality S34 Enuresis nocturna S185 Environmental risk S52 Erectile dysfunction S137 Escitalopram S160 Essential fatty acids S66 Estrogen S77 Euthymia S158 Evidence based treatment S41 Executive functions S176 Exercise S91 Extrapyramidal side effects S144, S165 Eye movement desensitization and reprocessing S123 Fear of negative evaluation scale S173
Female adolescents S125 Female reproductive hormones S193 Fish oil S135 Flight safety S103 Fluanxol S129 Fluoxetine S113, S130, S147, S179, S194 FMRI S62, S108, S189 Foetality S171 Follow-up S176 Forced swimming test S166 Forensic S202 Forensic psychiatric examination S128 Functional outcomes S136 Functional remission S188 Functioning S86 GABA S51 Galactorrhea S147, S160 Ganser Syndrome S159 Gating S49 Gender S140 Generalized anxiety disorder S193 Generalized convulsion S118 Genes S52 Genetic S68S 100 Genetic association S46 Genetic polymorphism S131, S132 Genomic diagnostics S157 GFAP S169 Ginseng augmentation therapy S114 Glia S50, S51 Glossodynia S161 Glutamate S40, S49, S50, S51, S69, S70 Glutathione S169 Glycine S50 GOT S116 GPT S116 Guidelines S98, S100 GWAS S157, S198 Hallucination S121 Haloperidol S129 Happiness S34 Harm minimization S42 Health S34 Hematological S130 Heroin S109 Hippocampal neurogenesis S91 HIV/AIDS S42 HLA-system S46 Hoarding S134 Homework assignments S41 HPA axis S51 Human characteristics S34 Human cognition S108, S189 Huntington’s disease S152 Hyperammonemic encephalopathy S164 Hyperprolactinemia S124, S135, S160 Hypersexual disorders S52 Hypersomnia S44 Hypochondriasis S105 Hypoglycemia S78 Hypomania S194 Hyponatremia S139, S141 Hypothalamic-pituitary-thyroid axis S77 ICAM-1 S143 Imipramine S185 Immunosuppresive treatment S161 Impulse control disorder S53 Impulsivity S94 In vitro analysis S115 Inappropriate medications S168 Individualized medicine S101 Inflammation S184 Information processing disorder S49 Inpatient S191 Insight 188 Insomnia S139 Insulin S78 Insulin resistance S78 Interethnic differences S131 Iron deficiency S74 Isolated thrombocytopenia S190 Ketamine S49, S69 Lack of self confidence S111 Lactation S48, S71, S71 Lamotrigine S142 Lateral ventricle S61 Learning S112 Leukopenia S127 Lipid peroxidation S140 Lithium S169 Lithium carbonate S161 Locomotor activity S141 Long QTc S119 Losartan S132 Lung functions 141 Magnetic resonance imaging S61 Maintenance S176 Maintenance phase S100 Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org Subject Index Major depressive disorder S115 Male patient S195 Malondialdehyde S169 Management S95 Mania S157, S194 Manic episode S124 Marital conflict S144, S184 Mechanism of action S63 Medical care S156 Medical decision support systems S157 Medical diseases S67 Medical marijuana S37 Medication S40, S43 Mega cisterna magna S195 Melatonin S75 Mental diseases S200 Mental disorder S144, S184 Mental health S154 Mental illness S196 Mental symptom S123, S135 Mentalizing S56 Metabolic syndrome S180 Metabolic S171 Metabolic side effect S140 Methadone S35, S114 Methadone substitution therapy S137 Methylphenidate S139, S190 Metoprolol S119 METU-SNP S102, S157 MGLU receptors S70 Middle-aged male S139 Mindfulness S40, S105 Mirtazapine S139, S175, S190, S196 Mixed mania S98 Modafinil S44 Models S49 Molecular diagnostics S102 Mood S89, S91, S153 Mood disorder S77, S79, S134, S149, S162 Mood stabiliser S149 MRI S62 Music therapy S191 Myeloperoxidase S46, S169 NADPH-oxidase S46 Neuroactive steroids S50, S51 Neurocognitive functions S193 Neurodegeneration S90, S91 Neurodevelopment S49 Neurodevelopmental disorders S75 Neurogenesis S193 Neuroimaging S36, S62, S148 Neuroleptic malignant syndrome S125 Neurological S201 Neurological co-morbidity, treatment S97 Neurological deficits S164 Neuromodulation S117 Neuropathic pain S59 Neuroplasticity S90 Neuroprotection S112 Neuroprotective effect S90 Neuroregeneration S91 Neurotrophic factors S70 Neutropenia S127 Nicotine S112 Nitric oxide S50 NMDA S40, S70 NMDA receptor S49, S69 Non-seasonal affective disorder S89 Normal pressure hydrocephalus S169 Nutraceuticals S108, S153, S189 Nymphomania S52 Obesity S94 Obsessive beliefs S137 Obsessive compulsive behavior S126 Obsessive compulsive disorder S71, S134, S176, S177 Obsessive compulsive spectrum S182 Obstructive sleep apnea S200 Occupation S58 OCD S59, S137, S172 Olanzapine S171, S180, S190 Olfaction S193 Oman S145 Omega fatty acids S75 Omega-3 fatty acids S64 Ontogenesis S171 Opioid dependence S35 Opioid withdrawal syndrome S114 Orally disintegrating olanzapine S115 Outpatient forensic psychiatric examination S181 Oxford S202 Oxidative stress S170, S189 Oxytocin S76, S133, S118 P value S104 Pain S54, S55, S81, S82 Pain reflex 141 Pain threshold S178 Paliperidone S165 Panic disorder S78, S106, S122, S137, S189, S71
Page 1 and 2:
With Contributions of
Page 3 and 4:
Turkish Association for Psychopharm
Page 5 and 6:
Nihat ALPAY Rüstem AŞKIN Ömer AY
Page 7 and 8:
NOVEMBER 23, 2011 WEDNESDAY TIME HA
Page 9 and 10:
NOVEMBER 25, 2011 FRIDAY AT A GLANC
Page 11 and 12:
13.30 15.00-16.00 17.30-19.30 17.30
Page 13 and 14:
09.00-10.30 PS-04: Adult attention
Page 15 and 16:
20.30-22.30 KC-01: Biostatistics -
Page 17 and 18:
09.00-10.30 PS-09: From preclinical
Page 19 and 20:
09.00-10.30 PS-10: Will glutamaterg
Page 21 and 22:
09.00-10.30 JS-05: Indian Psychiatr
Page 23 and 24:
NOVEMBER 26, 2011 SATURDAY 09.00-10
Page 25 and 26:
NOVEMBER 27, 2011 SUNDAY 09.00-10.3
Page 27 and 28:
Author(s) Abstracts of the Invited
Page 29 and 30:
Author(s) Abstracts of the Invited
Page 31 and 32:
Author(s) Poster Presentation 16 A.
Page 33 and 34:
Author(s) Poster Presentation 60 Ba
Page 35:
Author(s) Poster Presentation 108 O
Page 38 and 39:
Abstracts of the Invited Speakers O
Page 40 and 41:
Abstracts of the Invited Speakers p
Page 42 and 43:
Abstracts of the Invited Speakers D
Page 44 and 45:
Abstracts of the Invited Speakers R
Page 46 and 47:
Abstracts of the Invited Speakers [
Page 48 and 49:
Abstracts of the Invited Speakers H
Page 50 and 51:
Abstracts of the Invited Speakers m
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Abstracts of the Invited Speakers d
Page 58 and 59:
Abstracts of the Invited Speakers e
Page 60 and 61:
Abstracts of the Invited Speakers d
Page 62 and 63:
Abstracts of the Invited Speakers S
Page 64 and 65:
Abstracts of the Invited Speakers o
Page 66 and 67:
Abstracts of the Invited Speakers N
Page 68 and 69:
Abstracts of the Invited Speakers I
Page 70 and 71:
Abstracts of the Invited Speakers E
Page 72 and 73:
Abstracts of the Invited Speakers G
Page 74 and 75:
Abstracts of the Invited Speakers T
Page 76 and 77:
Abstracts of the Invited Speakers A
Page 78 and 79:
Abstracts of the Invited Speakers l
Page 80 and 81:
Abstracts of the Invited Speakers E
Page 82 and 83:
Page 84 and 85:
Abstracts of the Invited Speakers i
Page 86 and 87:
Abstracts of the Invited Speakers
Page 88 and 89:
Page 90 and 91:
Abstracts of the Invited Speakers A
Page 92 and 93:
Abstracts of the Invited Speakers P
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Abstracts of the Invited Speakers O
Page 100 and 101:
Abstracts of the Invited Speakers T
Page 102 and 103:
Abstracts of the Invited Speakers e
Page 104 and 105:
Abstracts of the Invited Speakers o
Page 106 and 107:
Abstracts of the Invited Speakers S
Page 108 and 109:
Abstracts of the Invited Speakers C
Page 110 and 111:
Page 112 and 113:
Abstracts of Oral Presentations [SO
Page 114 and 115:
Abstracts of Oral Presentations Mat
Page 116 and 117:
Abstracts of Oral Presentations wit
Page 118 and 119:
Abstracts of Oral Presentations pat
Page 120 and 121:
Abstracts of Oral Presentations ade
Page 122 and 123:
Abstracts of Oral Presentations eff
Page 124 and 125:
Turkish Association for Psychopharm
Page 126 and 127:
Poster Presentations behavior by ex
Page 128 and 129:
Poster Presentations [PP-005] Ref.
Page 130 and 131:
Poster Presentations fulfilling the
Page 132 and 133:
Page 134 and 135:
Poster Presentations eating disorde
Page 136 and 137:
Poster Presentations Conclusion: Th
Page 138 and 139:
Poster Presentations had no treatme
Page 140 and 141:
Poster Presentations 80 mg/day (dos
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Poster Presentations Based on the r
Page 156 and 157:
Page 158 and 159: Poster Presentations [PP-054] Ref.
Page 160 and 161: Poster Presentations study, the Cro
Page 168 and 169: Poster Presentations motivations fo
Page 172 and 173: Poster Presentations 4. Şükrü Ka
Page 176 and 177: Poster Presentations References: 1.
Page 178 and 179: Poster Presentations when meeting a
Page 180 and 181: Poster Presentations MADRS and HAM-
Page 182 and 183: Poster Presentations in terms of co
Page 184 and 185: Poster Presentations schizophrenia
Page 186 and 187: Poster Presentations ascending dopa
Page 188 and 189: Poster Presentations study. The inc
Page 190 and 191: Poster Presentations and Spaniards.
Page 192 and 193: Poster Presentations patients, and
Page 200 and 201: Poster Presentations 22.7%, bipolar
Page 202 and 203: Poster Presentations future, we exp
Page 204 and 205: Poster Presentations of action, ami
Page 206 and 207: Poster Presentations pharmacologica
Page 210 and 211: Panic symptoms S122 Paroxetine S156
Page 212 and 213: Etli T. S162 Evren C. S80, S154, S1
show all

SYMPOSIA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?